Finally, late recurrences were rare, but were significantly more frequent in patients with p16− tumors, but nevertheless, the prognosis for recurrent disease was poor independent of the HPVDNA+/−/p16+/− status of the tumor. This evidence concerns the gene CDKN2A and neoplasm.